Virtify Successfully Completes EMA's PIM Test Simulation

Virtify Successfully Completes EMA's PIM Test Simulation
 
 Virtify's PIM Enterprise software application certified after successful completion of the EMA's Test Simulation Program for the new Product Information Management (PIM) Standard
CAMBRIDGE, Mass., Oct. 13 /PRNewswire/ -- Virtify, Inc. has successfully completed the European Medicines Agency's (EMA) PIM Test Simulation program. This certification validates the efficacy of Virtify's PIM Enterprise software in generating technically valid PIM Submissions, importing agency responses, processing agency comments, counter proposing comments and correctly maintaining the life cycle of the entire submission.

Virtify entered into the simulation to test the full 277-day life cycle of PIM submissions using Virtify PIM Enterprise in an accelerated, 45-day test sequence. The multi-language and translation management features of Virtify PIM Enterprise were also tested, including English, Bulgarian (a Cyrillic language) and French. Virtify included these in the submission to ensure that the application could handle a wide variety of languages, including management of linguistic comments.

"Successfully completing the EMA Test Simulation is an important milestone for Virtify PIM Enterprise," said Satish Tadikonda, president and CEO of Virtify. "Virtify PIM Enterprise will help our customers achieve significant productivity gains through implementation of the new PIM standard in their labeling processes."

Virtify will be presenting PIM Enterprise during a special spotlight session at the Product Information Management conference organized by Informa Life Sciences in Amsterdam on October 14 - 15, 2010.

About Virtify

Virtify is the market leader in Structured Content Management software solutions for life sciences. Organizations rely on Virtify solutions to reduce costs, mitigate risk, and accelerate time-to-market by managing and automating the complex regulatory compliance and content exchange requirements throughout the product life cycle. Virtify's easy-to-use software suite is the industry's only solution to provide a secure, collaborative Web-based environment for managing regulated content throughout the entire product continuum - from pre-clinical through product registration to commercialization. Virtify's product suite includes software products for Global Labeling, Clinical Trial Disclosure, and Structured Content Management. The company plays a leadership role in the development of global regulatory standards and is an active participant in a variety of standards committees. Virtify's software products combined with comprehensive professional services and deep domain expertise enhance quality and compliance for some of the world's leading life sciences companies.

 

SOURCE Virtify, Inc.

Back to top
RELATED LINKS
http://www.virtify.com

 

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.